Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
Top Cited Papers
Open Access
- 23 October 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 38 (1), e3
- https://doi.org/10.1093/nar/gkp841
Abstract
For the past 15–20 years, the intracellular delivery and silencing activity of oligodeoxynucleotides have been essentially completely dependent on the use of a delivery technology (e.g. lipofection). We have developed a method (called ‘gymnosis’) that does not require the use of any transfection reagent or any additives to serum whatsoever, but rather takes advantage of the normal growth properties of cells in tissue culture in order to promote productive oligonucleotide uptake. This robust method permits the sequence-specific silencing of multiple targets in a large number of cell types in tissue culture, both at the protein and mRNA level, at concentrations in the low micromolar range. Optimum results were obtained with locked nucleic acid (LNA) phosphorothioate gap-mers. By appropriate manipulation of oligonucleotide dosing, this silencing can be continuously maintained with little or no toxicity for >240 days. High levels of oligonucleotide in the cell nucleus are not a requirement for gene silencing, contrary to long accepted dogma. In addition, gymnotic delivery can efficiently deliver oligonucleotides to suspension cells that are known to be very difficult to transfect. Finally, the pattern of gene silencing of in vitro gymnotically delivered oligonucleotides correlates particularly well with in vivo silencing. The establishment of this link is of particular significance to those in the academic research and drug discovery and development communities.Keywords
This publication has 16 references indexed in Scilit:
- G3139, an Anti-Bcl-2 Antisense Oligomer That Binds Heparin-Binding Growth Factors and Collagen I, AltersIn vitroEndothelial Cell Growth and Tubular MorphogenesisClinical Cancer Research, 2009
- Locked Nucleic Acid: Properties and Therapeutic AspectsPublished by Royal Society of Chemistry (RSC) ,2008
- Telomerase targeted oligonucleotide thio‐phosphoramidates in T24‐luc bladder cancer cellsJournal of Cellular Biochemistry, 2007
- Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificityAdvanced Drug Delivery Reviews, 2007
- Characterization of Antisense Oligonucleotides Comprising 2′‐Deoxy‐2′‐Fluoro‐β‐d‐Arabinonucleic Acid (FANA)Annals of the New York Academy of Sciences, 2006
- Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodiesNature Cell Biology, 2005
- Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma CellsClinical Cancer Research, 2004
- Toxicogenomics of Non-viral Vectors for Gene Therapy: A Microarray Study of Lipofectin- and Oligofectamine-induced Gene Expression Changes in Human Epithelial CellsJournal of Drug Targeting, 2003
- LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognitionTetrahedron, 1998
- Site and Mechanism of Antisense Inhibition by C-5 Propyne OligonucleotidesBiochemistry, 1995